OBJECTIVE： To observe therapeutic efficacy and safety of Shuxuetong injection combined with rosuvastatin in the treatment of angina pectoris after acute myocardial infarction. METHODS： The information of 68 patients with angina pectoris after acute myocardial infarction were collected retrospectively and divided into control group （34 cases） and study group （34 cases）. Based on routine treatment， control group was given Rosuvastatin calcium tablet 10 mg orally， once a day. Study group was additionally given Shuxuetong injection 6 mL added into 0.9％ Sodium chloride injection 250 mL intravenously， once a day， on the basis of control group. Both groups were treated for 14 days. Clinical efficacies of 2 groups were observed， and the levels of platelet activation markers （CD62p， CD63， PAC-1， LPA）， vascular endothelial growth function indexes （NO， ET-1， VEGF） were observed before and after treatment. The occurrence of ADR was observed. RESULTS： The total response rate of the study group was （94.12％） was significantly higher than that of control group （73.53％）， with statistical significance （P＜0.05）. After treatment， the levels of platelet activation markers， ET-1 and VEGF of 2 groups were significantly lower than before treatment， the study group was significantly lower than the control group； the levels of NO in 2 groups were significantly higher than before treatment， the study group was significantly higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Shuxuetong injection combined with rosuvastatin show significant therapeutic efficacy for angina pectoris after acute myocardial infarction， which can effectively improve vascular endothelial growth function and platelet function， without increasing the occurrence of ADR.